Cardiac resynchronization therapy pacemaker

Cardiac resynchronization therapy pacemaker has been studied in 4 papers since 2016: 4 observational studies in people. The newest paper, Nov 2, 2023: “Outcomes following cardiac resynchronisation therapy in older people”.

4 papers study it1 findingUpdated Nov 2, 2023

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“However, this difference lost significance after adjusting for baseline differences between the groups (HR 1.18, 95% CI 0.78-1.77, P = 0.435).”

Studies of cardiac resynchronization therapy pacemaker measured 1 outcome; the most studied are mortality (1 study).

Mortality

no changein humans1HR 1.18

1 study

Cardiac resynchronization therapy pacemaker was not clearly linked with mortality in humans (HR 1.18, 95% CI 0.78-1.77, P = 0.435).
“However, this difference lost significance after adjusting for baseline differences between the groups (HR 1.18, 95% CI 0.78-1.77, P = 0.435).”
Humansheart failure, LV ejection fraction ≤35%, QRS duration >120 ms; adjusted for baseline differences40.8 monthsn = 512
Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator
Journal of cardiovascular electrophysiologyFeb 10, 2016